tezosentan has been researched along with triclosan in 1 studies
Studies (tezosentan) | Trials (tezosentan) | Recent Studies (post-2010) (tezosentan) | Studies (triclosan) | Trials (triclosan) | Recent Studies (post-2010) (triclosan) |
---|---|---|---|---|---|
157 | 29 | 33 | 3,373 | 379 | 1,772 |
Protein | Taxonomy | tezosentan (IC50) | triclosan (IC50) |
---|---|---|---|
Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 0.585 | |
Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Escherichia coli K-12 | 0.4995 | |
Carbonyl reductase [NADPH] 1 | Homo sapiens (human) | 0.4 | |
Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Haemophilus influenzae Rd KW20 | 0.19 | |
Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Bacillus subtilis subsp. subtilis str. 168 | 0.5 | |
Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 2.8712 | |
Enoyl-[acyl-carrier-protein] reductase [NADH] | Francisella tularensis subsp. tularensis SCHU S4 | 1.9125 | |
Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI | Staphylococcus aureus subsp. aureus MRSA252 | 0.4976 | |
Enoyl-acyl carrier reductase | Toxoplasma gondii | 0.0167 | |
Enoyl-acyl-carrier protein reductase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.0872 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
1 other study(ies) available for tezosentan and triclosan
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |